Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) fair value: what the stock is really worth
As of Oct 9, 2026: fair value of Profarma Distribuidora de Produtos Farmacêuticos S.A BRL 21.33, price BRL 9.03, upside +136.2%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range R$2.40 – R$9.31 · fair‑value band R$16.00 – R$26.67 · the R$9.03 price screens below the R$21.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Profarma Distribuidora de Produtos Farmacêuticos in your weekly email
Every Wednesday you see whether Profarma Distribuidora de Produtos Farmacêuticos is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution of pharmaceutical products in Brazil. It offers pharmaceutical, personal hygiene, and beauty products. The company operates retail stores under the Drogasmil, Farmalife, Tamoio, and Rosário brands.
Show more
Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution of pharmaceutical products in Brazil. It offers pharmaceutical, personal hygiene, and beauty products. The company operates retail stores under the Drogasmil, Farmalife, Tamoio, and Rosário brands. The company was incorporated in 1961 and is headquartered in Rio De Janeiro, Brazil.
Stock analysis
Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) currently trades at R$9.03, while our model-based Fair Value estimate is R$21.33, implying the stock looks roughly 57.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of R$41.08 per share, and 22 of the 26 models we run sit above the R$9.03 price.
Bear case: the Dividend Discount group reads lowest at R$6.92, and 4 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: R$16.00 (bear) to R$26.67 (bull), the price of R$9.03 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Profarma Distribuidora de Produtos Farmacêuticos S.A reported revenue of R$11.5B in FY2025 versus R$6.4B in FY2021, a compound +15.6%/yr. Reported net income was R$119M in FY2025, compounding +11.0%/yr from FY2021.
Key figures
Market cap R$1.1B (≈ $222M) · P/E ratio 7.2 · P/S ratio 0.07 · EPS (TTM) R$1.26 · Dividend yield 8.4% · Net margin 1.0% · Return on equity 9.8% · Return on assets (EBIT) 4.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 136%, PFRM3 screens cheaper than that median.
Fair Value models
Bear R$16.00Fair Value R$21.33Bull R$26.67
Price R$9.03 · Upside +136.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$0.9769 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCFR$26.11R$43.04R$67.3179
Growth DCFR$25.57R$40.16R$59.5878
Residual IncomeR$8.50R$8.96R$9.8376
All 26 models by family
DCF Models
FCF DCFR$26.11R$43.04R$67.3179
Owner EarningsR$24.76R$40.89R$64.0275
5Y Revenue ExitR$25.29R$44.53R$70.3571
5Y EBITDA ExitR$35.72R$65.96R$103.8373
5Y P/E ExitR$17.60R$28.75R$41.0470
10Y Revenue ExitR$24.44R$41.08R$65.9565
10Y EBITDA ExitR$31.06R$54.48R$89.8166
10Y P/E ExitR$20.79R$31.21R$45.0664
Earnings-Based
Graham-DoddR$6.59R$30.44R$41.7964
Lynch FVR$8.01R$11.44R$14.8861
PEG = 1.0R$8.01R$11.44R$14.8857
EPVR$17.33R$19.73R$21.6874
Dividend Discount
Gordon GGMR$4.36R$7.30R$9.4768
DDM Multi-StageR$4.36R$6.92R$7.8567
Multiples
P/E MultipleR$16.00R$21.33R$26.6763
P/S MultipleR$12.36R$16.49R$20.6158
P/B MultipleR$12.36R$16.49R$20.6155
EV/EBITR$37.01R$50.23R$63.4666
EV/EBITDAR$47.14R$63.75R$80.3667
EV/RevenueR$25.65R$37.78R$49.9253
Asset-Based
NCAV (Graham)R$5.49R$7.35R$10.9854
Growth DCF
Growth DCFR$25.57R$40.16R$59.5878
Rev-Margin DCFR$25.29R$44.21R$68.5971
Economic Profit
Residual IncomeR$8.50R$8.96R$9.8376
ROIC CompounderR$18.96R$24.04R$30.0172
Growth Earnings
Growth-Adj P/ER$13.15R$18.79R$24.4267
P/S and P/B multiple show the same value here: both are capped by the same earnings anchor (earnings per share times 17), because margin and return on equity do not support the sector multiple.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
Start year 2020 (pandemic). Over 10 years: +12.7% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in BRL ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+26.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.8%
Dividend (yield on the price)8.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 3%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+4.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Brazil: IMF forecast 3.3% a year to 2030, 5.4% from 2016 to 2025) that is about +0.7% a year for the price.
Compare Profarma Distribuidora de Produtos Farmacêuticos S.A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+136.2% · Top 25%
Profitability
Return on equity (TTM)9.8% · Above median
Return on assets3.4% · Above median
Net margin (TTM)1.2% · Below median
Operating margin (TTM)2.9% · Below median
Growth and dividend
Revenue growth32.4% · Top 25%
Dividend yield (TTM)8.4% · Top 25%
Balance sheet
Debt / equity0.42× · Highest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Profarma Distribuidora de Produtos Farmacêuticos S.A Fair Value". https://www.fairvalue-calculator.com/stock/PFRM3
Frequently asked questions
Is Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of R$21.33 versus a price of R$9.03, about +136% upside (undervalued).
What is the fair value of PFRM3?
Our model-based fair value for Profarma Distribuidora de Produtos Farmacêuticos S.A is R$21.33 (as of Oct 2, 2026), built from audited fundamentals. The current price: R$9.03.
What is the quality score of PFRM3?
Profarma Distribuidora de Produtos Farmacêuticos S.A has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Our model-based price target is the fair value of R$21.33 (as of Oct 2, 2026) from 26 valuation models. Cautious scenario R$16.00, optimistic scenario R$26.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Profarma Distribuidora de Produtos Farmacêuticos S.A stock forecast for 2026?
Our models put fair value at R$21.33, about +136% upside versus a price of R$9.03 (undervalued). Cautious scenario R$16.00, optimistic scenario R$26.67. The calculation is refreshed regularly with new filings.
What is the revenue of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Profarma Distribuidora de Produtos Farmacêuticos S.A reported trailing-twelve-month revenue of about R$12.5B (latest available figure, as of Oct 2, 2026).
Does Profarma Distribuidora de Produtos Farmacêuticos S.A pay a dividend?
Profarma Distribuidora de Produtos Farmacêuticos S.A currently shows a dividend yield of about 8.44% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
For today's price to be fair in a discounted-cash-flow model, Profarma Distribuidora de Produtos Farmacêuticos S.A would have to grow free cash flow by +4.0 % per year for five years (discount rate 14.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.9 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of PFRM3 use?
Our models discount Profarma Distribuidora de Produtos Farmacêuticos S.A at 14.2 %: a base by market capitalisation (micro), damped by beta 0.34, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Profarma Distribuidora de Produtos Farmacêuticos S.A that is +4.0 % per year a year over ten years, using the same discount rate (14.2 %) and the same formula as our fair value.
How much growth has Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) delivered so far?
Over the past 5 years revenue at Profarma Distribuidora de Produtos Farmacêuticos S.A grew +15.9 % a year. The price currently implies +4.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) growing?
The median revenue growth in the sector is +5.4 % a year. That is the yardstick for the growth priced into Profarma Distribuidora de Produtos Farmacêuticos S.A (+4.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The free-cash-flow yield on the price is 17.17 %: that much free cash flow Profarma Distribuidora de Produtos Farmacêuticos S.A produces per unit of market value. When it exceeds the discount rate of our models (14.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Profarma Distribuidora de Produtos Farmacêuticos S.A it is R$21.33 per share (as of Oct 2, 2026), against a price of R$9.03. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Profarma Distribuidora de Produtos Farmacêuticos S.A stock overvalued or undervalued in 2026?
As of Oct 2, 2026, PFRM3 trades below its calculated fair value: price R$9.03, fair value R$21.33, a gap of about +136% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PFRM3?
No. The price is what the market pays today (R$9.03); the fair value is what the company's own numbers justify (R$21.33). For Profarma Distribuidora de Produtos Farmacêuticos S.A the two are R$12.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Profarma Distribuidora de Produtos Farmacêuticos S.A worth?
The market values Profarma Distribuidora de Produtos Farmacêuticos S.A at about R$1.1B (market capitalisation, as of Oct 2, 2026). Per share that is R$9.03; our models calculate a fair value of R$21.33 per share.
What do the bullish and bearish scenarios say about PFRM3?
Our models span a range for Profarma Distribuidora de Produtos Farmacêuticos S.A: cautious scenario R$16.00, base R$21.33, optimistic R$26.67 per share (as of Oct 2, 2026, price R$9.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PFRM3?
Profarma Distribuidora de Produtos Farmacêuticos S.A trades at a price-to-earnings ratio of 7.2 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$21.33 is built from several models across several years. Other multiples: PEG 0.9, P/B 0.8, P/S 0.1, EV/EBITDA 3.4.
What is the PEG ratio of PFRM3?
The PEG ratio of Profarma Distribuidora de Produtos Farmacêuticos S.A is 0.88 (P/E divided by earnings growth, as of Oct 2, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Balance-sheet figures for Profarma Distribuidora de Produtos Farmacêuticos S.A (as of Oct 2, 2026): return on equity 9.8%, debt of 0.42 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is PFRM3 from its 52-week high?
Profarma Distribuidora de Produtos Farmacêuticos S.A trades at R$9.03, about 3% below its 52-week high of R$9.31 and 47% above the low of R$6.16 (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of R$21.33 is for.
Which stocks are comparable to Profarma Distribuidora de Produtos Farmacêuticos S.A?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Profarma Distribuidora de Produtos Farmacêuticos S.A stock attractive at the current price?
The data as of Oct 2, 2026: price R$9.03, calculated fair value R$21.33 (+136%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PFRM3 calculated?
We run Profarma Distribuidora de Produtos Farmacêuticos S.A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$21.33, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Profarma Distribuidora de Produtos Farmacêuticos S.A currently trades 58 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The closing price on Oct 9, 2026 was R$9.03. Our model-based fair value is R$21.33, about +136% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Profarma Distribuidora de Produtos Farmacêuticos S.A right now?
The price is below even our cautious bear case (R$16.00). The market is more pessimistic than our downside scenario. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Profarma Distribuidora de Produtos Farmacêuticos S.A
How large is the market capitalisation of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The market capitalisation of Profarma Distribuidora de Produtos Farmacêuticos S.A is R$1.1B (≈ $222M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The price-to-sales ratio of Profarma Distribuidora de Produtos Farmacêuticos S.A is 0.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Earnings per share at Profarma Distribuidora de Produtos Farmacêuticos S.A are R$1.26 (price ÷ EPS = P/E 7.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The dividend yield of Profarma Distribuidora de Produtos Farmacêuticos S.A is 8.4% (payout 60.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The net margin of Profarma Distribuidora de Produtos Farmacêuticos S.A is 1.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The return on equity (ROE) of Profarma Distribuidora de Produtos Farmacêuticos S.A is 9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
On an EBIT basis the return on assets of Profarma Distribuidora de Produtos Farmacêuticos S.A is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
The operating margin of Profarma Distribuidora de Produtos Farmacêuticos S.A is 2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Revenue at Profarma Distribuidora de Produtos Farmacêuticos S.A is growing +32.4% versus a year earlier (3y avg +13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3)?
Earnings per share at Profarma Distribuidora de Produtos Farmacêuticos S.A are growing +225% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) carry?
The net debt of Profarma Distribuidora de Produtos Farmacêuticos S.A is R$1.2B (fiscal year 2025, ≈ 6.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Profarma Distribuidora de Produtos Farmacêuticos S.A in the live analysis
One click puts Profarma Distribuidora de Produtos Farmacêuticos S.A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
